FDA.reportPublic FDA data

1.9 ML elranatamab-bcmm 40 MG/ML Injection [Elrexfio]

RxCUI
2644894
RxNorm name
1.9 ML elranatamab-bcmm 40 MG/ML Injection [Elrexfio]
Display name
1.9 ML elranatamab-bcmm 40 MG/ML Injection [Elrexfio]
Full name
1.9 ML elranatamab-bcmm 40 MG/ML Injection [Elrexfio]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:28

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761345Elrexfioelranatamab-bcmm351(a)Rx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
f6fea598-ff58-4a20-b5e8-8a51f37d8bebELREXFIO 76 MG in 1.9 ML Injection [PSN] · 1.9 ML elranatamab-bcmm 40 MG/ML Injection [Elrexfio] [SBD] · 1.9 ML Elrexfio 40 MG/ML Injection [SY] · Elrexfio 76 MG per 1.9 ML Injection [SY]44These highlights do not include all the information needed to use ELREXFIO safely and effectively. See full prescribing information for ELREXFIO. ELREXFIO ® (elranatamab-bcmm) injection, for subcutaneous use Initial U.S. Approval: 202320260226